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LETTERS
Genomic Diversity 
of Oseltamivir- 
Resistant Influenza 
Virus A (H1N1), 
Luxembourg,  
2007–08 
To the Editor: The prevalence of 
oseltamivir-resistant influenza viruses 
A (H1N1) (ORVs) increased dramati-
cally worldwide during the winter of 
2007–08 (1). Recent reports indicat-
ed that by early 2009 most influenza 
virus  (H1N1)  strains  were  resistant 
to  oseltamivir  (2).  Resistant  viruses 
were transmitted readily and were as 
viable and pathogenic as oseltamivir-
sensitive  viruses  (OSVs)  (3,4).  The 
His275Tyr (N1 numbering) mutation 
in the neuraminidase (NA) genes of 
influenza virus A (H1N1) that confers 
resistance to oseltamivir has previous-
ly been associated with impaired virus 
replication,  infectivity,  and  pathoge-
nicity (5,6).
We investigated the genetic diver-
sity in all 8 gene segments of represen-
tative ORVs and OSVs collected during 
December  2007–March  2008  by  the 
National  Influenza  Sentinel  Surveil-
lance  System  in  Luxembourg  (www.
lns.public.lu/statistiques/grippe).  Phy-
logenetic  analyses  were  performed 
by using MEGA version 4.0 (7). Tree 
topology  and  posterior  probabilities 
were calculated by using MrBayes ver-
sion 3 (8). The sequences have been 
submitted to GenBank (accession nos. 
FM174406–60,  FN401430–45,  and 
FN401487–FN401518).
Among  140  viruses,  34  strains 
(24.3%) had the oseltamivir-resistant 
genotype  (Tyr275)  in  the  NA  gene. 
Bayesian  analyses  of  NA  genes 
showed that ORVs formed a distinct 
cluster  supported  by  high  posterior 
probability  (1.00)  on  the  common 
node  (Figure).  One  resistant  strain 
(LNS-365) was more closely related 
to  OSVs  (minimal  Kimura  distance 
0.3%,  4  nt)  than  to  ORVs  (minimal 
Kimura distance 0.5%, 6 nt). In NA 
protein, 33 ORVs showed the common 
Asp354Gly substitution in addition to 
the Tyr275 mutation. The resistant out-
lier LNS-365 encoded Asp354 like all 
other OSVs (n = 106). Similarly, only 
4 other resistant strains from Europe 
from the same season shared Asp354 
with  all  2007–08  sensitive  influenza 
virus (H1N1) strains (n = 251) avail-
able in public databases.
A total of 18–44 selected sequenc-
es  from  each  of  the  other  genes  of 
ORVs and OSVs were generated to in-
vestigate which other genetic markers 
cosegregated with the resistant geno-
type. Sequences derived from most of 
the other genes (polymerase  proteins 
PB1  and  PA,  hemagglutinin,  nucleo-
protein,  matrix  protein,  nonstructural 
protein) of ORVs and OSVs were phy-
logenetically interspersed with no dis-
tinct clustering. In contrast, matching 
the phylogeny of NA, PB2 sequences 
of genotypically resistant strains (n = 
14) formed a distinct cluster supported 
by high posterior probabilities (1.00) 
and separate from all OSVs (n = 16) 
and the resistant outlier LNS-365 (Fig-
ure). On the PB2 amino acid level, all 
OSVs and the resistant outlier LNS-
365 shared Pro453, whereas all ORV 
encoded  serine  at  the  same  position 
(Ser453).  The  outlier  LNS-365  dif-
fered only by 2 aa from OSVs but by 4 
aa from the closest resistant strain.
All published PB2 sequences for 
influenza  virus  (H1N1)  strains  col-
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Figure.	Phylogeny	of	A)	neuraminidase	(NA,	complete	gene)	and	B)	polymerase	complex	2	
(C-terminal	1,300	nt)	genes	for	selected	influenza	viruses	A	(H1N1)	from	Luxembourg	and	
other	countries.	Subclades	are	identified	to	the	right	of	each	tree.	The	best-approximating	
model	of	nucleotide	evolution	was	the	general	time	reversible	model	with	a	gamma	rate	
distribution	and	this	model	was	used	for	the	Bayesian	analysis.	Markov	chain	Monte	Carlo	
sampling	was	implemented	in	MrBayes	version	3	(8).	In	all	cases,	6	chains	with	at	least	4	
million	generations	were	calculated	(10%	burn-in	removed).	At	least	2	independent	runs	
of	each	analysis	were	performed.	Posterior	probabilities	(indicated	on	important	nodes)	of	
the	consensus	tree	topologies	were	estimated	by	sampling	likelihood	parameters	every	
125	generations.	Boldface	indicates	sequences	of	oseltamivir-resistant	influenza	viruses	
A	(H1N1)	with	the	Tyr275	mutation	in	NA.	In	MEGA	version	4,	a	neighbor-joining	tree	with	
10,000	replicates	was	generated	to	calculate	bootstrap	values,	shown	in	italics	on	the	node	
dividing	resistant	and	sensitive	strains.	Scale	bars	indicate	nucleotide	substitutions	per	site.	
The	trees	are	rooted	on	A/New	Caledonia/01/1999	and	A/BrevigMission/1918	(indicated	
by	arrows).LETTERS
lected since 1918 (n = 720) encoded 
either  Pro453  or  His453.  Until  the 
emergence of ORVs in 2007, Ser453 
was  only  present  in  3  other  strains 
(A/Wilson-Smith/1933  and  2  strains 
from 1976 and 1988). Located on the 
surface  of  the  PB2  cap-binding  do-
main (9), the Pro453Ser mutation may 
influence  polymerase  function  and 
virus  replication.  The  fact  that  PB2 
sequences  of  ORVs  and  OSVs  are 
phylogenetically  segregated  suggests 
a link between the genetic background 
and the unexpected fitness of ORVs. 
There was no amino acid mutation in 
any of the other genes that segregated 
in the same way between ORVs and 
OSVs other than Ser453 (PB2).
Only 1 OSV strain from Luxem-
bourg in 2007–08 (LNS-110) was de-
rived from subclade 2C, unlike the oth-
er 139 influenza virus (H1N1) strains 
(subclade 2B, Figure). Like many oth-
er subclade 2C strains, which were re-
cently identified, this virus encoded the 
amantadine-resistance  marker  Asn31 
in the matrix 2 protein (10). Although 
we did not identify any reassortments 
between  ORVs  and  OSVs,  double-
resistant  strains  may  result  from  co-
circulation of amantadine-resistant and 
ORVs in the same region.
The  phylogeny  of  ORVs  identi-
fied  worldwide  (2)  indicates  multi-
clonal emergence of resistance, which 
suggests that OSVs may contain low 
levels of ORV subpopulations. Using 
pyrosequencing,  we  determined  the 
incidence and level of mixed alleles in 
codon 275 of the NA gene (CAT, sen-
sitive and TAT, resistant). In 98 clini-
cal  specimens  (78  sensitive  and  20 
resistant  strains)  no  minority  alleles 
were reliably detected above the 3% 
threshold of the assay. Six OSVs with 
values between 2.1% and 2.9% were 
further analyzed by cloning of partial 
NA genes. No evidence of ORVs was 
found (Tyr275) in 227 clones.
In summary, we have described 
amino acid markers in NA (Gly354) 
and  PB2  (Ser453)  proteins,  which 
were present in ORVs but absent in 
all OSVs from Luxembourg in 2007–
08.  ORVs  without  this  background 
did not spread as efficiently and were 
rarely  found  in  Europe.  At  least  1 
resistant  virus  was  more  similar  to 
OSV,  which  suggests  >2  clones  of 
resistant viruses in Luxembourg, po-
tentially  with  different  viral  fitness. 
We speculate that the unexpected fit-
ness of the 2007–08 influenza viruses 
(H1N1) may be caused by a new ge-
netic background that is most likely 
encoded in the PB2 gene.
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Letters
Letters commenting on recent articles 
as well as letters reporting cases, out-
breaks, or original research are wel-
come. Letters commenting on articles 
should  contain  no  more  than  300 
words and 5 references; they are more 
likely  to  be  published  if  submitted 
within 4 weeks of the original article’s 
publication.  Letters  reporting  cases, 
outbreaks, or original research should 
contain  no  more  than  800  words 
and 10 references. They may have 1  
Figure or Table and should not be di-
vided into sections. All letters should 
contain material not previously pub-
lished and include a word count.